The team at DropGenie uses digital microfluidics to perform gene editing screens on small numbers of patient cells, accelerating the discovery of new drugs.
As a CD40 ligand antagonist, dazodalibep blocks immune cell communication, potentially serving as the first drug to target the autoimmune disease’s cause.
Researchers discovered an immunological connection between the eye and the brain that could lead to new therapeutics for central nervous system diseases.
T cells have long held the title of the ideal immune cells for CAR therapy, but recent discoveries are opening new possibilities for other immune cells.
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.